Daily Market Reports | Apr 30 2026
This story features A2 MILK COMPANY LIMITED, and other companies.
For more info SHARE ANALYSIS: A2M
The company is included in ASX100, ASX200, ASX300 and ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
A2M AMI (2) ATH B4P COH CSL DVP GGP (2) GHM KAR MMI MVF MYG ORI PNR RMD RWC SLS SNZ VUL
A2M A2 MILK COMPANY LIMITED
Dairy – Overnight Price: $7.13
Jarden rates ((A2M)) as Underweight (4) –
Jarden maintains an Underweight rating for a2 Milk Co with an unchanged target price of $9.20 as new legally binding testing requirements for China infant formula exports introduce near-term supply chain risks.
The New Zealand regulator recently implemented mandatory cereulide toxin testing for all infant formula batches destined for the Chinese market, requiring adherence to strict quantification limits of 0.1 micrograms per kilogram.
Commentary indicates the transition to these new standards is currently extending quality assurance release times and impacting product availability despite strong in-market execution.
While international peers switched arachidonic acid (ARA) suppliers to mitigate risk, the broker suggests a2 Milk faces a significant backlog of unfilled orders from its manufacturing partner Synlait Milk ((SM1)).
No changes were made to earnings forecasts in this update, leaving the projected financial year 2026 earnings per share at 28.1 cents.
This report was published on April 28, 2026.
Target price is $9.20 Current Price is $7.13 Difference: $2.07
If A2M meets the Jarden target it will return approximately 29% (excluding dividends, fees and charges).
Current consensus price target is $8.93, suggesting upside of 27.4%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 19.35 cents and EPS of 24.72 cents.
At the last closing share price the estimated dividend yield is 2.71%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 28.85.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 24.2, implying annual growth of N/A.
Current consensus DPS estimate is 17.8, implying a prospective dividend yield of 2.5%.
Current consensus EPS estimate suggests the PER is 29.0.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 60.08 cents and EPS of 29.38 cents.
At the last closing share price the estimated dividend yield is 8.43%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 24.27.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 28.8, implying annual growth of 19.0%.
Current consensus DPS estimate is 43.6, implying a prospective dividend yield of 6.2%.
Current consensus EPS estimate suggests the PER is 24.3.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AMI AURELIA METALS LIMITED
Gold & Silver – Overnight Price: $0.30
Moelis rates ((AMI)) as Buy (1) –
Moelis maintains a Buy rating for Aurelia Metals and reduces its target price to $0.42 from $0.44 after the March quarter production report demonstrated a strategic prioritisation of higher-value gold stopes.
Management subsequently upgraded FY26 gold guidance to a range of 45-50koz while reducing copper expectations to reflect individual commodity output and prevailing metal prices.
The report highlights record plant throughput alongside improving recoveries for both zinc and gold, supported by strong operational momentum at the Federation mine where mining rates reached an annualised 400ktpa.
The executing of a new $150m senior secured financing package and a $94.7m unrestricted cash balance are viewed as providing the flexibiity needed to fund the Peak plant expansion program and Great Cobar development.
The broker slightly increased cost assumptions to reflect the trajectory of actuals, resulting in minor downward revisions to near-term earnings estimates.
This report was published on April 28, 2026.
Target price is $0.42 Current Price is $0.30 Difference: $0.115
If AMI meets the Moelis target it will return approximately 38% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.63.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 5.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.35.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Shaw and Partners rates ((AMI)) as Buy (1) –
Shaw and Partners maintains a Buy rating for Aurelia Metals and lifts its target price to $0.50 from $0.42 following record gold production for the March quarter.
Operations delivered 13koz of gold, prompting management to upgrade full-year gold production guidance to a range of 45-50koz as higher-grade stopes at the Peak mine are prioritised.
The report notes free cash flow growth lifted unrestricted cash to $94.7m, while a new $150m senior secured financing package further fortifies the balance sheet ahead of critical FY27 growth phases.
The analysts significantly upgraded FY26 earnings per share forecasts by 40% to reflect revised gold price assumptions and the outperformance of the Federation mine.
Completion of the Peak processing plant expansion remains a key catalyst, with the transition toward a 1.2mtpa throughput capacity expected to structurally enhance profitability and lower unit operating costs.
This report was published on April 29, 2026.
Target price is $0.50 Current Price is $0.30 Difference: $0.195
If AMI meets the Shaw and Partners target it will return approximately 64% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 4.55.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 8.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 3.51.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ATH ALTERITY THERAPEUTICS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.01
Canaccord Genuity rates ((ATH)) as Speculative Buy (1) –
Canaccord Genuity highlights recent positive developments for Alterity Therapeutics. The FDA has confirmed no major changes are required to the company’s chemistry, manufacturing and control (CMC) plans for ATH434.
ATH434 is an oral small molecule designed to treat multiple system atrophy.
The FDA confirmation is seen as supporting timelines for an end-of-Phase II meeting in mid-2026, with manufacturing scale-up progressing in parallel.
The broker also notes encouraging data presented at the American Academy of Neurology, supporting ATH434’s treatment effect.
Commentary suggests development of the MuSyCA outcome measure may provide more robust clinical endpoints, reinforcing confidence in the drug’s potential.
Canaccord retains a Speculative Buy rating and target of 1.6c.
This report was published on April 29, 2026.
Target price is $0.02 Current Price is $0.01 Difference: $0.006
If ATH meets the Canaccord Genuity target it will return approximately 60% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 5.00.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 0.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 3.33.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
B4P BEFOREPAY GROUP LIMITED
Diversified Financials – Overnight Price: $1.48
Shaw and Partners rates ((B4P)) as Buy (1) –
Shaw and Partners maintains a Buy rating for Beforepay Group and lowers its target price to $2.70 from $3.00 following a mixed March quarter update.
The report highlights the successful scaling of the Personal Loan product with $4.9m in originations, which contributed roughly 20% to quarterly revenue growth.
While the core Pay Advance business delivered a robust net transaction margin supported by excellent credit management, operating expenses exceeded expectations due to business development costs within Carrington Labs.
While these costs have now stabilised, the broker reduced outer-year earnings forecasts by up to 19% and applied a higher risk-free discount rate to its valuation models.
Commentary suggests management continues to address a significant market opportunity for small borrowers with short durations, positioning the company for potential operating leverage as the loan receivables book matures.
This report was published on April 29, 2026.
Target price is $2.70 Current Price is $1.48 Difference: $1.225
If B4P meets the Shaw and Partners target it will return approximately 83% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of 14.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.10.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of 18.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.10.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
COH COCHLEAR LIMITED
Medical Equipment & Devices – Overnight Price: $90.00
Canaccord Genuity rates ((COH)) as Buy (1) –
Canaccord Genuity retains a Buy rating on Cochlear but cuts its target price sharply to $120 from $295 following a significant FY26 guidance downgrade.
Underlying profit guidance was reduced by -26%, driven by weaker demand, particularly in the US, disruptions in Europe and the Middle East, and China pricing constraints, the analysts explain.
The Middle East is estimated to contribute around 8%-10% of annual Cochlear implant (CI) sales, with volumes typically skewed toward the fourth quarter. The broker also factors into its forecasts restructuring costs, receivables risk and FX headwinds.
Despite the downgrade and multiple compression, Canaccord sees no new structural threat and believes valuation now better reflects fundamentals after removing the historical “market leader” premium.
This report was published on April 29, 2026.
Target price is $120.00 Current Price is $90.00 Difference: $30
If COH meets the Canaccord Genuity target it will return approximately 33% (excluding dividends, fees and charges).
Current consensus price target is $116.53, suggesting upside of 29.4%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is 421.9, implying annual growth of -29.0%.
Current consensus DPS estimate is 328.0, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 21.3.
Forecast for FY27:
Current consensus EPS estimate is 475.1, implying annual growth of 12.6%.
Current consensus DPS estimate is 366.2, implying a prospective dividend yield of 4.1%.
Current consensus EPS estimate suggests the PER is 18.9.
Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CSL CSL LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $125.78
Jarden rates ((CSL)) as Overweight (2) –
Jarden maintains an Overweight rating for CSL and reduces its target price to $244.00 from $270.00 after the US Food and Drug Administration proposed the withdrawal of the drug Tavneos.
Proposed removal of the treatment follows a failure to demonstrate efficacy and concerns regarding data integrity within the initial application process.
Tavneos revenues have subsequently been removed from its model, reducing financial year 2027 earnings per share forecasts by -1.1% to US695.6c.
Updates to risk-free rate assumptions and currency projections also contributed to the valuation reduction.
Commentary highlights growing headwinds for the Vifor portfolio, including the impending loss of exclusivity for Injectafer and generic competition in European markets.
This report was published on April 29, 2026.
Target price is $244.00 Current Price is $125.78 Difference: $118.22
If CSL meets the Jarden target it will return approximately 94% (excluding dividends, fees and charges).
Current consensus price target is $201.19, suggesting upside of 61.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 437.19 cents and EPS of 953.89 cents.
At the last closing share price the estimated dividend yield is 3.48%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.19.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 888.5, implying annual growth of N/A.
Current consensus DPS estimate is 438.6, implying a prospective dividend yield of 3.5%.
Current consensus EPS estimate suggests the PER is 14.0.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 446.77 cents and EPS of 1041.47 cents.
At the last closing share price the estimated dividend yield is 3.55%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 1045.2, implying annual growth of 17.6%.
Current consensus DPS estimate is 493.9, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 11.9.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
DVP DEVELOP GLOBAL LIMITED
Industrial Metals – Overnight Price: $5.50
Canaccord Genuity rates ((DVP)) as Speculative Buy (1) –
Develop Global had a strong March quarter, according to Canaccord Genuity, with Woodlawn achieving commercial production after exceeding steady-state run rates.
Operational momentum improved, the analyst highlights, with higher mined and processed tonnes, rising grades and strong copper and zinc production. It’s also noted reported revenue understated performance due to shipment timing.
The broker expects a materially stronger June quarter, supported by improved recoveries and revenue catch-up, while forecasting solid free cash flow (FCF) generation.
Canaccord also points to upside from mine life extension drilling, imminent final investment decision (FID) at Sulphur Springs and near-term lithium exposure via Pioneer Dome.
Canaccord maintains a Speculative Buy rating and raises its target by $1.00 to $7.00.
This report was published on April 29, 2026.
Target price is $7.00 Current Price is $5.50 Difference: $1.5
If DVP meets the Canaccord Genuity target it will return approximately 27% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GGP GREATLAND RESOURCES LIMITED
Gold & Silver – Overnight Price: $13.99
Jarden rates ((GGP)) as Underweight (4) –
Jarden maintains an Underweight rating for Greatland Resources and lifts its target price to $8.50 from $8.30 following a record quarter of free cash generation.
Commentary notes the recent receipt of Federal environmental approval for the Havieron project significantly de-risks the development timeline.
Operations at Telfer delivered a production beat during the March quarter, underpinned by robust material movements and lower-than-anticipated processing costs.
FY26 earnings per share forecast is upgraded to 121.7c from 111.3c to reflect these strong operational outcomes and a higher net cash balance of $1.2bn.
The suggestion made is the current market valuation remains stretched as the business prepares for a capital-intensive transition phase before steady-state production from new development programs begins in early 2029.
This report was published on April 29, 2026.
Target price is $8.50 Current Price is $13.99 Difference: minus $5.49 (current price is over target).
If GGP meets the Jarden target it will return approximately minus 39% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $16.67, suggesting upside of 25.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 121.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.50.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 117.4, implying annual growth of 84.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 61.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.67.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 72.5, implying annual growth of -38.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 18.3.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Moelis rates ((GGP)) as Sell (5) –
Moelis maintains a Sell rating for Greatland Resources and lifts its target price to $11.90 from $11.50 after incorporating a strong March quarter production result.
Robust throughput and head grades at the mature Telfer asset underpinned a significant beat in cash generation, lifting the closing cash balance to $1,208m.
The report highlights the commencement of a complex transition period where legacy mine plans give way to capital-intensive redevelopment and the eventual commissioning of Havieron.
Fundamental valuation remains stretched compared to broader gold sector coverage, with the current share price trading at a 16% premium to the broker’s fair value assessment.
While organic exploration success at West Dome Underground provides long-term resource upside, a projected reduction in free cash flow during the upcoming development program could pressure medium-term sentiment.
This report was published on April 28, 2026.
Target price is $11.90 Current Price is $13.99 Difference: minus $2.09 (current price is over target).
If GGP meets the Moelis target it will return approximately minus 15% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $16.67, suggesting upside of 25.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 123.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 11.30.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 117.4, implying annual growth of 84.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.3.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 111.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.60.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 72.5, implying annual growth of -38.2%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 18.3.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GHM GOLDEN HORSE MINERALS LIMITED
Gold & Silver – Overnight Price: $0.47
Shaw and Partners rates ((GHM)) as Buy (1) –
Shaw and Partners maintains a Buy rating and a $1.50 target price for Golden Horse Minerals following “standout” March quarter drilling results across the Hopes Hill corridor.
Aggressive exploration involving 34km of drilling confirmed high-grade gold mineralisation at surface, at depth, and across a 2.5km strike extent.
Petrographic analysis successfully confirmed the gold is free-milling, a technical milestone expected to reduce future processing complexity and overall costs.
Management ramped up to five rigs as part of a fully funded 125km drilling program designed to define the emerging vertically extensive system.
With $39.3m in cash and 9,000 pending assay results, the broker anticipates steady momentum ahead of a maiden resource estimate targeted for late 2026.
This report was published on April 29, 2026.
Target price is $1.50 Current Price is $0.47 Difference: $1.025
If GHM meets the Shaw and Partners target it will return approximately 216% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 22.62.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 27.94.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
KAR KAROON ENERGY LIMITED
Crude Oil – Overnight Price: $2.14
Jarden rates ((KAR)) as Buy (1) –
Jarden maintains a Buy rating for Karoon Energy and keeps its target price at $2.55 following a March quarter update marked by operational disruptions.
The report notes group production missed estimates by -5% because of a riser leak at the Who Dat asset and timing delays for oil liftings in Brazil.
Management increased 2026 capital expenditure guidance to -$150-183m to fund additional sidetrack drilling intended to mitigate the Who Dat output loss.
The broker reduced FY26 earnings estimates to US35.0c from US35.4c, reflecting these production setbacks and higher costs associated with the Brazil maintenance program.
Free cash flow is expected to improve materially in the second half of 2026 as production is restored and capital spending declines, aided by a higher oil price environment.
This report was published on April 29, 2026.
Target price is $2.55 Current Price is $2.14 Difference: $0.41
If KAR meets the Jarden target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $2.07, suggesting downside of -4.8%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 19.17 cents and EPS of 52.40 cents.
At the last closing share price the estimated dividend yield is 8.96%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 4.08.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 23.7, implying annual growth of N/A.
Current consensus DPS estimate is 4.8, implying a prospective dividend yield of 2.2%.
Current consensus EPS estimate suggests the PER is 9.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 19.17 cents and EPS of 52.10 cents.
At the last closing share price the estimated dividend yield is 8.96%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 4.11.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 22.5, implying annual growth of -5.1%.
Current consensus DPS estimate is 4.7, implying a prospective dividend yield of 2.2%.
Current consensus EPS estimate suggests the PER is 9.6.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MMI METRO MINING LIMITED
Coal – Overnight Price: $1.36
Shaw and Partners rates ((MMI)) as Buy (1) –
Shaw and Partners maintains a Buy rating for Metro Mining and lifts its target price to $3.00 from $0.15 (post consolidation) following a successful navigation of the record wet season.
March shipments of 100kt represented the highest monthly volume on record despite site demobilisation due to cyclonic activity impacting the transhipping channel.
The report highlights a significant freight advantage over high-cost Guinea production, with the company locking in $8-9 per tonne rates through the next two years.
Minor downward adjustments were made to near-term earnings models to account for elevated fuel and consumable expenses associated with the Ikamba transhipper maintenance program.
Management expects the expanded 7.0m metric tonnes per annum production capacity to drive substantial free cash flow as Chinese refineries increasingly rely on imported bauxite.
This report was published on April 29, 2026.
Target price is $3.00 Current Price is $1.36 Difference: $1.64
If MMI meets the Shaw and Partners target it will return approximately 121% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
Forecast for FY26:
Shaw and Partners forecasts a full year FY26 dividend of 15.00 cents and EPS of 14.50 cents.
At the last closing share price the estimated dividend yield is 11.03%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.38.
Forecast for FY27:
Shaw and Partners forecasts a full year FY27 dividend of 30.00 cents and EPS of 44.80 cents.
At the last closing share price the estimated dividend yield is 22.06%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 3.04.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MVF MONASH IVF GROUP LIMITED
Healthcare services – Overnight Price: $0.73
Canaccord Genuity rates ((MVF)) as Hold (3) –
Canaccord Genuity highlights ongoing challenges for the fertility sector, with weak stimulated cycle numbers in Victoria and Queensland potentially slowing Monash IVF’s market share recovery.
National data show fresh cycles declined -4.4% year-on-year and frozen embryo transfers fell -1.2%, implying an estimated -3% organic decline in cycles after adjusting for Monash’s footprint.
The broker considers the recently rejected 90cps bid for Monash IVF is broadly fair relative to its own 86c valuation.
Canaccord Genuity retains a Hold rating.
This report was published on April 29, 2026.
Target price is $0.86 Current Price is $0.73 Difference: $0.13
If MVF meets the Canaccord Genuity target it will return approximately 18% (excluding dividends, fees and charges).
Current consensus price target is $0.83, suggesting upside of 12.6%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 3.00 cents.
At the last closing share price the estimated dividend yield is 4.11%.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.1, implying annual growth of -20.6%.
Current consensus DPS estimate is 2.7, implying a prospective dividend yield of 3.6%.
Current consensus EPS estimate suggests the PER is 14.5.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 4.00 cents.
At the last closing share price the estimated dividend yield is 5.48%.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 5.5, implying annual growth of 7.8%.
Current consensus DPS estimate is 3.1, implying a prospective dividend yield of 4.2%.
Current consensus EPS estimate suggests the PER is 13.5.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MYG MAYFIELD GROUP HOLDINGS LIMITED
Overnight Price: $2.48
Moelis rates ((MYG)) as Initiation of coverage with Buy (1) –
Moelis initiates coverage on Mayfield Group with a Buy rating and $2.65 price target, highlighting its strong position in critical electrical infrastructure.
Record work in hand of $135m and a significant manufacturing footprint expansion should underpin near-term growth within the electrification and data centre markets.
Successful execution in addressable utility and industrial sectors, alongside the recent acquisition of SMEC Power & Technology, contributes to robust earnings momentum.
Favourable industry tailwinds from the AI infrastructure build-out and ongoing energy transition are projected to drive a 24% two-year earnings per share compound annual growth rate.
The broker introduces underlying earnings per share forecasts of 8.6 cents for FY26 and 11.2 cents for FY27, with dividend projections set at 3.1 cents and 4.1 cents, respectively.
This report was published on April 29, 2026.
Target price is $2.65 Current Price is $2.48 Difference: $0.17
If MYG meets the Moelis target it will return approximately 7% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 3.10 cents and EPS of 8.60 cents.
At the last closing share price the estimated dividend yield is 1.25%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 28.84.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 4.10 cents and EPS of 11.20 cents.
At the last closing share price the estimated dividend yield is 1.65%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 22.14.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ORI ORICA LIMITED
Mining Sector Contracting – Overnight Price: $20.93
Jarden rates ((ORI)) as Overweight (2) –
Jarden maintains an Overweight rating for Orica and lowers its target price to $24.20 from $24.60 ahead of the first-half result.
Modest earnings revisions reflect a cash settlement with CF Industries Holdings, Inc anticipated to occur in the second half of FY26.
Digital Solutions and Specialty Mining Chemicals divisions currently drive nearly 75% of incremental group earnings, successfully offsetting translation headwinds in the core Blasting Solutions segment.
Resilient demand for gold continues to support the market position of the mining chemicals business, the broker points out.
Commentary suggests risk-reward symmetry has improved considerably following recent underperformance against the broader index.
This report was published on April 28, 2026.
Target price is $24.20 Current Price is $20.93 Difference: $3.27
If ORI meets the Jarden target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $26.19, suggesting upside of 25.1%(ex-dividends)
The company’s fiscal year ends in September.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 63.00 cents and EPS of 125.10 cents.
At the last closing share price the estimated dividend yield is 3.01%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.73.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 121.1, implying annual growth of 261.1%.
Current consensus DPS estimate is 62.5, implying a prospective dividend yield of 3.0%.
Current consensus EPS estimate suggests the PER is 17.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 78.00 cents and EPS of 129.10 cents.
At the last closing share price the estimated dividend yield is 3.73%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.21.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 135.9, implying annual growth of 12.2%.
Current consensus DPS estimate is 70.2, implying a prospective dividend yield of 3.4%.
Current consensus EPS estimate suggests the PER is 15.4.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PNR PANTORO GOLD LIMITED
Gold & Silver – Overnight Price: $3.27
Moelis rates ((PNR)) as Buy (1) –
Moelis retains a Buy rating for Pantoro Gold and lifts the target price to $5.31 from $4.90 despite a softer-than-expected March quarter production result.
Operations suffered from a confluence of weather-related disruptions and significant loader downtime at Scotia underground, while the flooding remnants of Cyclone Mitchell further impacted ore haulage.
Management is incorporating high-grade third-party ore from the Rama open pit into the mill program to help bridge the production gap and meet revised guidance mid-points.
Commentary indicates current share price levels present an attractive entry point given identification of identifiable transitional factors rather than structural medium-term issues.
The broker upgraded FY26 earnings estimates to 41.0 cents per share from 39.0 cents to reflect higher realised gold prices and the rolling forward of its valuation model.
This report was published on April 28, 2026.
Target price is $5.31 Current Price is $3.27 Difference: $2.04
If PNR meets the Moelis target it will return approximately 62% (excluding dividends, fees and charges).
Current consensus price target is $6.17, suggesting upside of 89.3%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 41.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.98.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 48.5, implying annual growth of 227.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 6.7.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 61.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.31.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 70.7, implying annual growth of 45.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 4.6.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RMD RESMED INC
Medical Equipment & Devices – Overnight Price: $30.35
Jarden rates ((RMD)) as Overweight (2) –
Jarden maintains an Overweight rating for ResMed and reduces the target price to $44.80 from $45.20 ahead of the third-quarter result.
Earnings per share forecasts for FY26 were slightly trimmed to reflect a mark-to-market loss on a venture investment, while outer-year estimates were upgraded due to more favourable exchange rate assumptions.
Operational momentum remains high with the company recovering previously ceded market share in the US continuous positive airway pressure segment.
It is suggested the mask category will continue acting as a primary growth engine, supported by the recent acquisition of VirtuOx and a robust manufacturing program.
Commentary highlights gross margins are projected to expand as currency headwinds diminish and software license sales improve the business mix.
This report was published on April 29, 2026.
Target price is $44.80 Current Price is $30.35 Difference: $14.45
If RMD meets the Jarden target it will return approximately 48% (excluding dividends, fees and charges).
Current consensus price target is $46.66, suggesting upside of 56.5%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 37.13 cents and EPS of 168.29 cents.
At the last closing share price the estimated dividend yield is 1.22%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.03.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 155.5, implying annual growth of N/A.
Current consensus DPS estimate is 34.8, implying a prospective dividend yield of 1.2%.
Current consensus EPS estimate suggests the PER is 19.2.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 41.77 cents and EPS of 193.59 cents.
At the last closing share price the estimated dividend yield is 1.38%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.68.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 174.2, implying annual growth of 12.0%.
Current consensus DPS estimate is 38.8, implying a prospective dividend yield of 1.3%.
Current consensus EPS estimate suggests the PER is 17.1.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RWC RELIANCE WORLDWIDE CORP. LIMITED
Building Products & Services – Overnight Price: $3.24
Jarden rates ((RWC)) as Overweight (2) –
Jarden maintains an Overweight rating for Reliance Worldwide and reduces the target price to $4.00 from $4.30 following the Q3 trading update.
Management reaffirmed FY26 guidance while confirming net tariff impacts will likely land at the lower end of the previously indicated $25-30m range.
Recent regulatory shifts including the US Supreme Court striking down IEEPA tariffs provide a potential windfall via refund claims.
The report trimmed outer-year earnings estimates by -2-4% to account for mark-to-market copper pricing and updated exchange rate assumptions.
Capital returns remain a central thesis pillar with achievement of the $120m buyback expected within the current half alongside forecasted organic margin expansion.
This report was published on April 28, 2026.
Target price is $4.00 Current Price is $3.24 Difference: $0.76
If RWC meets the Jarden target it will return approximately 23% (excluding dividends, fees and charges).
Current consensus price target is $3.89, suggesting upside of 20.9%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 6.74 cents and EPS of 23.36 cents.
At the last closing share price the estimated dividend yield is 2.08%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.87.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 21.6, implying annual growth of N/A.
Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 1.8%.
Current consensus EPS estimate suggests the PER is 14.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 8.38 cents and EPS of 30.99 cents.
At the last closing share price the estimated dividend yield is 2.59%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.45.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 27.9, implying annual growth of 29.2%.
Current consensus DPS estimate is 7.2, implying a prospective dividend yield of 2.2%.
Current consensus EPS estimate suggests the PER is 11.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SLS SOLSTICE MINERALS LIMITED
Copper – Overnight Price: $1.47
Canaccord Genuity rates ((SLS)) as Speculative Buy (1) –
Solstice Minerals generated encouraging early drilling results from its Nanadie project, assesses Canaccord Genuity, with visible copper mineralisation extending well below the existing resource.
The first diamond hole confirms continuity at depth, with chalcopyrite observed across broad intervals, suggesting to the broker potential to significantly expand the current resource footprint.
While assays are pending, strong potential is anticipated for material resource growth given Nanadie’s favourable location and scale in a tight copper exploration market.
Canaccord retains a Speculative Buy rating and target of $1.85.
This report was published on April 29, 2026.
Target price is $1.85 Current Price is $1.47 Difference: $0.38
If SLS meets the Canaccord Genuity target it will return approximately 26% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SNZ SUMMERSET GROUP HOLDINGS LIMITED
Aged Care & Seniors – Overnight Price: $6.58
Jarden rates ((SNZ)) as Neutral (3) –
Summerset Group receives a Neutral rating and a $10.52 price target from Jarden following a comprehensive review of its Australian expansion history.
The report highlights the group’s ambitious delivery targets across the Tasman, with management aiming for roughly 300 units in FY27 from a portfolio currently sitting at only 200 units and beds.
This growth trajectory represents a significant leap of faith compared to the history of the New Zealand program, Jarden comments, where a similar delivery scale was achieved on a far more established portfolio of 2,300 units.
Commentary suggests the upcoming investor day remains critical to addressing moderate sales cadence and providing visibility on cash recycling assumptions amid a NZ$2bn group net debt position.
While asset value growth from the first four Australian sites is projected to exceed NZ$550m on completion, it is suggested the near-term supply chain risks and start-up operating losses continue to warrant a cautious stance.
This report was published on April 28, 2026.
Target price is $10.52 Current Price is $6.58 Difference: $3.94
If SNZ meets the Jarden target it will return approximately 60% (excluding dividends, fees and charges).
Current consensus price target is N/A
The company’s fiscal year ends in December.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 20.76 cents and EPS of minus 2.82 cents.
At the last closing share price the estimated dividend yield is 3.15%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 233.75.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 90.1, implying annual growth of N/A.
Current consensus DPS estimate is 20.3, implying a prospective dividend yield of 3.1%.
Current consensus EPS estimate suggests the PER is 7.3.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 20.76 cents and EPS of 2.29 cents.
At the last closing share price the estimated dividend yield is 3.15%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 287.71.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 98.3, implying annual growth of 9.1%.
Current consensus DPS estimate is 20.8, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 6.7.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VUL VULCAN ENERGY RESOURCES LIMITED
New Battery Elements – Overnight Price: $3.95
Canaccord Genuity rates ((VUL)) as Speculative Buy (1) –
Canaccord Genuity highlights a key milestone for Vulcan Energy Resources, with construction commencing on the Lionheart central lithium chemicals plant in Frankfurt.
The start of full-scale build, alongside prior progress at upstream operations, is seen as an important de-risking step toward first production targeted in 2028.
Lionheart Phase One is designed to produce 24ktpa of lithium hydroxide, supporting Europe’s battery supply chain, the analyst explains.
Ongoing progress across drilling, construction and cost control are considered key value drivers.
Canaccord retains a Speculative Buy rating and target of $10.75.
This report was published on April 29, 2026.
Target price is $10.75 Current Price is $3.95 Difference: $6.8
If VUL meets the Canaccord Genuity target it will return approximately 172% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.
This company reports in EUR. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
<span style="
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: A2M - A2 MILK COMPANY LIMITED
For more info SHARE ANALYSIS: AMI - AURELIA METALS LIMITED
For more info SHARE ANALYSIS: ATH - ALTERITY THERAPEUTICS LIMITED
For more info SHARE ANALYSIS: B4P - BEFOREPAY GROUP LIMITED
For more info SHARE ANALYSIS: COH - COCHLEAR LIMITED
For more info SHARE ANALYSIS: CSL - CSL LIMITED
For more info SHARE ANALYSIS: DVP - DEVELOP GLOBAL LIMITED
For more info SHARE ANALYSIS: GGP - GREATLAND RESOURCES LIMITED
For more info SHARE ANALYSIS: GHM - GOLDEN HORSE MINERALS LIMITED
For more info SHARE ANALYSIS: KAR - KAROON ENERGY LIMITED
For more info SHARE ANALYSIS: MMI - METRO MINING LIMITED
For more info SHARE ANALYSIS: MVF - MONASH IVF GROUP LIMITED
For more info SHARE ANALYSIS: MYG - MAYFIELD GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: ORI - ORICA LIMITED
For more info SHARE ANALYSIS: PNR - PANTORO GOLD LIMITED
For more info SHARE ANALYSIS: RMD - RESMED INC
For more info SHARE ANALYSIS: RWC - RELIANCE WORLDWIDE CORP. LIMITED
For more info SHARE ANALYSIS: SLS - SOLSTICE MINERALS LIMITED
For more info SHARE ANALYSIS: SM1 - SYNLAIT MILK LIMITED
For more info SHARE ANALYSIS: SNZ - SUMMERSET GROUP HOLDINGS LIMITED
For more info SHARE ANALYSIS: VUL - VULCAN ENERGY RESOURCES LIMITED